Meet us at the DIA and BIO International conventions

DIABIO1

 

 

 

This June, NDA will be attending the DIA USA and BIO convention with a strong line-up of world-leading speakers and experts.

The 53rd DIA Annual Meeting 2017 is being held on June 18-22, at McCormick Place, Chicago. Whilst, the BIO International Convention is on June 19-22, at San Diego Convention Center, San Diego.

If you are planning to attend this year’s DIA or BIO, we would really like to meet up with you. If you’d like to arrange a meeting with us, please email anna.perrin@ndareg.com.

Hear the experts

NDA’s experts will present on a number of critical drug development related topics at both the DIA and the BIO meeting.

NDA at DIA USA

Neelu AgarwalPete_TaftNeelu Agrawal, Principal, PharmApprove

Pete Taft, Founder and Chief Executive Officer, Taft and Partners/PharmApprove

 

Tutorial:  Preparing for a US FDA Advisory Committee Meeting
Track: 5 Regulatory Affairs #30
Day: Sunday June 18
Time: 13:00 – 16:30

Shelley_GandhiShelley Gandhi, Pharmacovigilance and Drug safety Expert expert, NDA Group
Title: The Good Pharmacovigilance Practices in the EU: Global Applications
Track: 6 Safety & PV #43
Day: Sunday June 18
Time: 09:00 – 17:00

Title:  Future Regulatory Goals of the Periodic Benefit-Risk Evaluation Reports (PBRER ): Are They Being Achieved?
Track: 6 Safety & PV #280 Developing Pharmacovigilance Policy based on Impact
Day: Tuesday June 20
Time: 16:00 – 17:15

Lesley_WiseLesley Wise, Principal Consultant, Pharmacoepidemiology, NDA Group
Title: Incorporating Patient Preferences in Benefit-Risk Assessments: Interpreting ICH M4E (R2)
Track: 4 Patient Engagement, Forum #251 Defining the Science of Patient Input to Enhance Drug Development & Approval: Regulatory
Day: Tuesday June 20
Time: 14:00 – 15:15

 


NDA at BIO USA

Lisa-PelusoMarkku ToivonenLisa Peluso, Director Coaching and Client Engagement, PharmApprove

Markku Toivonen, Scientific Director, NDA Group

 

Title: Bridging the Atlantic: How to Involve Patients in Orphan Drug Development and Approval Processes Given Differences between FDA and EMA
Day: Wednesday June 21
Time: 15:00 – 16:00 Room 3

 


To find out more or schedule an appointment with members of the NDA team, please email anna.perrin@ndareg.com

We look forward to hearing back from you about a meeting and to seeing you at the events!

 

About NDA
NDA Group is a leading global drug development consultancy providing small as well as large, multi-national pharmaceutical companies with strategic advice and operational support to get good medicines to market and keep them there. Based in Boston, London, Munich, New Jersey, Stockholm and Zurich, NDA offers a range of professional drug development consulting services that spans from early development phase to lifecycle management of a medicinal product. These services span Development Strategy, Translational Science, Procedure & Submission Management, High-Stakes Meetings and Process Design & Optimisation. Clients are supported by a team of over 150 regulatory affairs, health technology assessment, pharmacovigilance, quality assurance and strategic communications professionals. Backing all major NDA projects is the unique NDA Advisory Board comprising industry experts, many of whom are ex- European Agency and FDA staff. Learn more at www.ndareg.com and follow them at www.linkedin.com/company/nda-group-ab.

About PharmApprove
The NDA PharmApprove team comprises leading strategic, regulatory, and scientific communications professionals. PharmApprove focuses on strategic and tactical support to companies facing high-profile, high-stakes events and engagements anywhere along the road to approval and commercialization – including FDA Advisory Committee meetings. PharmApprove helps clients win health authority approvals, deliver compelling regulatory communications, and make persuasive pharmacoeconomic arguments to payers and HTAs. Learn more at http://www.pharmapprove.com/ and follow them socially at twitter.com/pharmapprove.